24/7 Customer Support

Opioid Withdrawal Syndrome (OWS) Market - Industry Dynamics, Market Size, And Opportunity Forecast To 2030

Global Opioid Withdrawal Syndrome (OWS) Market- (By Therapy- Lucemyra (Lofexidine), Methadone, Buprenorphine, Naltrexone and Others (Britlofex, Masimo Bridge, etc.); and By Country) - Industry Dynamics, Market Size and Opportunity Forecast, 2030

  • Published On: 19-Apr-2022  |  Format: pdfpowerpointexcel  |  Report ID: AA0422201
    Delivery: 2 to 4 Hours

FREQUENTLY ASKED QUESTIONS

Opioids are a class of drugs that are commonly prescribed to treat pain. Opioids include both opiates (drugs derived from the opium poppy, including morphine, codeine, heroin and opium) and synthetic opioids like hydrocodone, oxycodone and methadone which have similar effects.

Opioid withdrawal syndrome is a life-threatening condition resulting from opioid dependence. Opioids are a group of drugs which produce mental relaxation, pain relief and euphoric feelings. Chronic use of opioids leads to the development of an incapacitating form of dependence in users.

Common signs of opioid withdrawal include anxiety, restlessness, insomnia, vomiting and others.

The global opioid withdrawal syndrome (OWS) market is studied from 2018-2030. 

Only one non-opioid drug, Lucemyra has received an FDA approval till date. 

The growth rate of the global opioid withdrawal syndrome (OWS) market is 10.4%, with an estimated value of US$ 2,633.4 Million by 2030. 

US held the major share in terms of revenue in the global opioid withdrawal syndrome (OWS) market in 2021. 

Factors such as increasing cases of opioid addiction and increasing engagement by private and public institutions drives the growth in the global opioid withdrawal syndrome (OWS) market.

Adverse side effects of opioids are a restraining factor which inhibits the growth of the global opioid withdrawal syndrome market during the forecast period. 

Buprenorphine holds the largest market share in 2021 as it has long half-life, high potency and ceiling effect’ for both euphoric sensation and adverse effects make it an optimal treatment alternative for patients presenting to the ED with opioid withdrawal.

The diagnosis and treatable OWS cases are continuously increasing in the Germany. Opioid therapy in the treatment of chronic pain conditions in Germany is highly considered. 

Family services, child care services, vocational services, mental health services, medical services, educational services, HIV/AIDS services, legal services, financial services, housing /transportation services. 

The key players operating in the market include US Worldmeds LLC, Aphios Corporation, Chiesi Farmaceutici S.p.A., Titan Pharmaceuticals, Inc., BioDelivery Sciences International, Inc., Alkermes and Indivior PLC among others.